Biocon-Mylan’s Biosimilar For Cancer Drug Pegfilgrastim Gets U.S. FDA Nod
Ten milligram tablets of the hyperactivity drug, Adderall, made by Shire Plc, is shown in a Cambridge, Massachusetts (Photographer: JB Reed/Bloomberg News ) 

Biocon-Mylan’s Biosimilar For Cancer Drug Pegfilgrastim Gets U.S. FDA Nod

Biocon Ltd. and its partner Mylan N.V. have received approval for their first biosimilar of cancer medicine pegfilgrastim from the U.S. drug regulator for selling in the American market.Their drug,...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.